Provided by Tiger Trade Technology Pte. Ltd.

Arvinas Holding Company LLC

7.41
-0.0200-0.27%
Post-market: 7.28-0.1300-1.75%19:30 EDT
Volume:585.12K
Turnover:4.33M
Market Cap:484.51M
PE:55.43
High:7.52
Open:7.51
Low:7.30
Close:7.43
52wk High:14.51
52wk Low:6.97
Shares:65.39M
Float Shares:56.67M
Volume Ratio:0.81
T/O Rate:1.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.1337
EPS(LYR):-1.1400
ROE:1.59%
ROA:-1.01%
PB:0.86
PE(LYR):-6.50

Loading ...

Arvinas Q2 Operating Income USD 164.1 Million

Reuters
·
Aug 04

Arvinas Swings to FY26 Q2 Net Income of $169.4 Million; Revenue More than Doubled to $249.7 Million

Reuters
·
Aug 04

Arvinas Q2 EPS $2.58 Beats $(0.44) Estimate, Sales $249.700M Beat $32.542M Estimate

Benzinga Earnings
·
Aug 04

Arvinas Q2 Operating Expenses USD 85.6 Million

THOMSON REUTERS
·
Aug 04

Arvinas Q2 Net Income USD 169.4 Million

THOMSON REUTERS
·
Aug 04

Arvinas - Cash Position Expected to Fund Operations into Second Half of 2028

THOMSON REUTERS
·
Aug 04

Arvinas Shareholders Elect Two Directors at Annual Meeting

Reuters
·
Jun 26

Arvinas CMO Noah Berkowitz to depart July 3, company starts search for successor

Reuters
·
Jun 23

Rigel Pharmaceuticals pays $70 million upfront for global rights to Arvinas-Pfizer breast cancer drug VEPPANU

Reuters
·
Jun 18

Rigel Deal for VEPPANU Cleared, Arvinas Receives Payment

TIPRANKS
·
Jun 17

BRIEF-Arvinas - Pfizer, And Rigel Receive Hart-Scott-Rodino Clearance For License Agreement On June 11, 2026

Reuters
·
Jun 17

Arvinas - Pfizer, and Rigel Receive Hsr Clearance for License Agreement on June 11, 2026 - SEC Filing

THOMSON REUTERS
·
Jun 17

Arvinas - Co and Pfizer Eligible for up to $320 Mln in Milestone Payments and Tiered Royalties - SEC Filing

THOMSON REUTERS
·
Jun 17

Rigel closes VEPPANU license deal, makes USD 70 million upfront payment

Reuters
·
Jun 17

Arvinas joins MJFF-backed PPMI study to support development of LRRK2 degrader ARV-102 for Parkinson’s

Reuters
·
Jun 04

Arvinas Joins the Michael J. Fox Foundation’s Lite and Ppmi Programs to Advance New Therapies Targeting Lrrk2 for Parkinson’s Disease

THOMSON REUTERS
·
Jun 04

Arvinas Price Target Maintained With a $18.00/Share by Stephens & Co.

Dow Jones
·
Jun 03

Analysts Conflicted on These Healthcare Names: Arvinas Holding Company (ARVN), Lyell Immunopharma (LYEL) and Relay Therapeutics (RLAY)

TIPRANKS
·
Jun 03

Arvinas Holding Company (ARVN) Gets a Buy from Barclays

TIPRANKS
·
Jun 03

Arvinas - Expects Cash Position as of March 31, 2026 to Fund Operations Into Second Half of 2028 - SEC Filing

THOMSON REUTERS
·
Jun 03